180 related articles for article (PubMed ID: 17804044)
1. Chemotherapy for recurrent cervical cancer.
Cadron I; Van Gorp T; Amant F; Leunen K; Neven P; Vergote I
Gynecol Oncol; 2007 Oct; 107(1 Suppl 1):S113-8. PubMed ID: 17804044
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy for recurrent cervical cancer.
Pectasides D; Kamposioras K; Papaxoinis G; Pectasides E
Cancer Treat Rev; 2008 Nov; 34(7):603-13. PubMed ID: 18657909
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy for recurrent and metastatic cervical cancer.
Tao X; Hu W; Ramirez PT; Kavanagh JJ
Gynecol Oncol; 2008 Sep; 110(3 Suppl 2):S67-71. PubMed ID: 18533239
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy for recurrent cervical carcinoma.
Moore DH
Curr Opin Oncol; 2006 Sep; 18(5):516-9. PubMed ID: 16894302
[TBL] [Abstract][Full Text] [Related]
5. Management of metastatic cervical cancer: review of the literature.
Long HJ
J Clin Oncol; 2007 Jul; 25(20):2966-74. PubMed ID: 17617528
[TBL] [Abstract][Full Text] [Related]
6. A feasibility study of topotecan with standard-dose cisplatin and concurrent primary radiation therapy in locally advanced cervical cancer.
Gatcliffe TA; Tewari KS; Shah A; Brewster WR; Burger RA; Kuo JV; Monk BJ
Gynecol Oncol; 2009 Jan; 112(1):85-9. PubMed ID: 18977518
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy in the management of cervical carcinoma.
duPont NC; Monk BJ
Clin Adv Hematol Oncol; 2006 Apr; 4(4):279-86. PubMed ID: 16728939
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy for advanced and recurrent cervical carcinoma: results from cooperative group trials.
Leath CA; Straughn JM
Gynecol Oncol; 2013 Apr; 129(1):251-7. PubMed ID: 23280089
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy in advanced and recurrent cervical cancer. A review.
Park RC; Thigpen JT
Cancer; 1993 Feb; 71(4 Suppl):1446-50. PubMed ID: 8431878
[TBL] [Abstract][Full Text] [Related]
10. Novel chemotherapy approaches in chemoradiation protocols.
González-Cortijo L; Carballo N; González-Martín A; Corraliza V; Chiva de Agustín L; Lapuente Sastre F; García García JF; Rojo Sebastián A; Hornedo J; Colomer R
Gynecol Oncol; 2008 Sep; 110(3 Suppl 2):S45-8. PubMed ID: 18678399
[TBL] [Abstract][Full Text] [Related]
11. Recent achievements and future developments in advanced and recurrent cervical cancer: trials of the Gynecologic Oncology Group.
Tewari KS; Monk BJ
Semin Oncol; 2009 Apr; 36(2):170-80. PubMed ID: 19332251
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy for stage IVB or recurrent cancer of the uterine cervix.
Omura GA
J Natl Cancer Inst Monogr; 1996; (21):123-6. PubMed ID: 9023841
[TBL] [Abstract][Full Text] [Related]
13. Unexpected long-term survival without evidence of disease after salvage chemotherapy for recurrent metastatic cervical cancer: a case series.
Khoury-Collado F; Bowes RJ; Jhamb N; Aghajanian C; Abu-Rustum NR
Gynecol Oncol; 2007 Jun; 105(3):823-5. PubMed ID: 17363045
[TBL] [Abstract][Full Text] [Related]
14. [Medical treatment of metastatic or recurrent cancer of the cervix].
de la Motte Rouge T; Pautier P; Hamy AS; Duvillard P; Bruna A; Castaigne D; Morice P; Haie-Meder C; Lhommé C
Bull Cancer; 2006 Mar; 93(3):263-70. PubMed ID: 16567313
[TBL] [Abstract][Full Text] [Related]
15. Topotecan in combination with cisplatin for the treatment of stage IVB, recurrent, or persistent cervical cancer.
Brave M; Dagher R; Farrell A; Abraham S; Ramchandani R; Gobburu J; Booth B; Jiang X; Sridhara R; Justice R; Pazdur R
Oncology (Williston Park); 2006 Oct; 20(11):1401-4, 1410; discussion 1410-11, 1415-6. PubMed ID: 17112001
[TBL] [Abstract][Full Text] [Related]
16. Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer.
Herzog TJ; Powell MA; Rader JS; Gibb RK; Lippmann L; Coleman RL; Mutch DG
Gynecol Oncol; 2008 Dec; 111(3):467-73. PubMed ID: 18834619
[TBL] [Abstract][Full Text] [Related]
17. A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma.
Downs LS; Judson PL; Argenta PA; Ghebre R; Geller MA; Bliss RL; Boente MP; Nahhas WA; Abu-Ghazaleh SZ; Chen MD; Carson LF
Cancer; 2008 Jan; 112(2):331-9. PubMed ID: 18058810
[TBL] [Abstract][Full Text] [Related]
18. Topotecan combined with carboplatin in recurrent epithelial ovarian cancer: results of a single-institutional phase II study.
Kang H; Kim TJ; Lee YY; Choi CH; Lee JW; Bae DS; Kim BG
Gynecol Oncol; 2009 Aug; 114(2):210-4. PubMed ID: 19446320
[TBL] [Abstract][Full Text] [Related]
19. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
Meier W; du Bois A; Reuss A; Kuhn W; Olbricht S; Gropp M; Richter B; Lück HJ; Kimmig R; Pfisterer J
Gynecol Oncol; 2009 Aug; 114(2):199-205. PubMed ID: 19446314
[TBL] [Abstract][Full Text] [Related]
20. Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.
Ozols RF
J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S60-73. PubMed ID: 19780247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
